TARBP2-Enhanced Resistance during Tamoxifen Treatment in Breast Cancer

TARBP2-Enhanced Resistance during Tamoxifen Treatment in Breast Cancer

Tamoxifen is the most widely used hormone therapy in estrogen receptor-positive (ER+) breast cancer, which accounts for approximately 70% of all breast cancers. Although patients who receive tamoxifen therapy benefit with respect to an improved overall prognosis, resistance and cancer recurrence sti...

Full description

Bibliographic Details
Main Authors: Ming-Yang Wang, Hsin-Yi Huang, Yao-Lung Kuo, Chiao Lo, Hung-Yu Sun, Yu-Jhen Lyu, Bo-Rong Chen, Jie-Ning Li, Pai-Sheng Chen
Format: Article
Language:English
Published: MDPI AG 2019-02-01
Series:Cancers
Subjects:
tamoxifen
hormone therapy
TARBP2
SOX2
merlin
Online Access:https://www.mdpi.com/2072-6694/11/2/210

Similar Items

Similar Items